JP2005510491A - 免疫抑制を逆転させるための免疫治療 - Google Patents

免疫抑制を逆転させるための免疫治療 Download PDF

Info

Publication number
JP2005510491A
JP2005510491A JP2003537573A JP2003537573A JP2005510491A JP 2005510491 A JP2005510491 A JP 2005510491A JP 2003537573 A JP2003537573 A JP 2003537573A JP 2003537573 A JP2003537573 A JP 2003537573A JP 2005510491 A JP2005510491 A JP 2005510491A
Authority
JP
Japan
Prior art keywords
cells
ncm
antigen
administering
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003537573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510491A5 (enExample
Inventor
ジョン ダブリュー． ヘイデン，
Original Assignee
イミュノ−アールエックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノ−アールエックス， インコーポレイテッド filed Critical イミュノ−アールエックス， インコーポレイテッド
Publication of JP2005510491A publication Critical patent/JP2005510491A/ja
Publication of JP2005510491A5 publication Critical patent/JP2005510491A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003537573A 2001-10-26 2002-10-26 免疫抑制を逆転させるための免疫治療 Pending JP2005510491A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34450901P 2001-10-26 2001-10-26
PCT/US2002/034361 WO2003035004A2 (en) 2001-10-26 2002-10-26 Immunotherapy for reversing immune suppression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009139689A Division JP2009197032A (ja) 2001-10-26 2009-06-10 免疫抑制を逆転させるための免疫治療

Publications (2)

Publication Number Publication Date
JP2005510491A true JP2005510491A (ja) 2005-04-21
JP2005510491A5 JP2005510491A5 (enExample) 2006-01-05

Family

ID=23350824

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003537573A Pending JP2005510491A (ja) 2001-10-26 2002-10-26 免疫抑制を逆転させるための免疫治療
JP2009139689A Pending JP2009197032A (ja) 2001-10-26 2009-06-10 免疫抑制を逆転させるための免疫治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009139689A Pending JP2009197032A (ja) 2001-10-26 2009-06-10 免疫抑制を逆転させるための免疫治療

Country Status (7)

Country Link
US (3) US7731945B2 (enExample)
EP (2) EP1446159A4 (enExample)
JP (2) JP2005510491A (enExample)
AU (1) AU2002342151B2 (enExample)
CA (1) CA2498591A1 (enExample)
MX (1) MXPA04003864A (enExample)
WO (1) WO2003035004A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544724A (ja) * 2006-07-25 2009-12-17 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
JP2005510491A (ja) 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
WO2005043155A1 (en) 2003-10-21 2005-05-12 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
BRPI0518571A2 (pt) * 2004-12-06 2008-11-25 Sciclone Pharmaceuticals Inc peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
AU2008329741B2 (en) * 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
RU2385875C2 (ru) * 2008-04-24 2010-04-10 Ибмед Холдингс Лимитед Пептид, обладающий ростостимулирующей активностью гранулоцитарного колониестимулирующего фактора человека
RU2374262C1 (ru) * 2008-05-22 2009-11-27 Ибмед Холдингс Лимитед Олигопептид, обладающий активностью фактора стволовых клеток csf по отношению к дифференцировке тимоцитов
ES2565779T3 (es) 2008-09-02 2016-04-06 Cedars-Sinai Medical Center Epítopos CD133
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
WO2010129895A2 (en) 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Cd133 epitopes
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
US20150030635A1 (en) * 2012-03-15 2015-01-29 Macrocure, Ltd. Activated Immunostimulatory Cell Composition and Uses Thereof
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509955A (ja) * 1994-11-17 1998-09-29 ユニヴァーシティ オブ サウス フロリダ 二次性免疫不全症の治療法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4470926A (en) * 1980-01-18 1984-09-11 Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4464355A (en) 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
DE3120912A1 (de) * 1981-05-26 1982-12-16 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von p-nitrophenetol
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) * 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5354580A (en) * 1993-06-08 1994-10-11 Cvd Incorporated Triangular deposition chamber for a vapor deposition system
EP0789588B1 (en) * 1994-11-17 2005-01-19 University Of South Florida Method for making a medicament for treating secondary immunodeficiency
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0974357A1 (en) * 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2950109C (en) * 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
JP2005510491A (ja) 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509955A (ja) * 1994-11-17 1998-09-29 ユニヴァーシティ オブ サウス フロリダ 二次性免疫不全症の治療法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544724A (ja) * 2006-07-25 2009-12-17 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
JP2013189480A (ja) * 2006-07-25 2013-09-26 Irx Therapeutics Inc ワクチン免疫療法
JP2016029100A (ja) * 2006-07-25 2016-03-03 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
JP2017155059A (ja) * 2006-07-25 2017-09-07 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法

Also Published As

Publication number Publication date
EP1446159A4 (en) 2005-06-01
US7731945B2 (en) 2010-06-08
EP1446159A2 (en) 2004-08-18
CA2498591A1 (en) 2003-05-01
WO2003035004A9 (en) 2003-12-31
MXPA04003864A (es) 2004-08-11
JP2009197032A (ja) 2009-09-03
WO2003035004A2 (en) 2003-05-01
WO2003035004A3 (en) 2003-11-06
US20110044941A1 (en) 2011-02-24
US20130164255A1 (en) 2013-06-27
US20030124136A1 (en) 2003-07-03
AU2002342151B2 (en) 2007-07-19
EP1810691A2 (en) 2007-07-25
EP1810691A3 (en) 2008-03-26

Similar Documents

Publication Publication Date Title
JP2009197032A (ja) 免疫抑制を逆転させるための免疫治療
JP5963688B2 (ja) 免疫抑制された患者のためのワクチン免疫療法
JP6162778B2 (ja) ワクチン免疫療法
JP2012144579A (ja) 免疫抑制された患者のためのワクチン免疫治療
AU2002342151A1 (en) Immunotherapy for reversing immune suppression
US20100310469A1 (en) Vaccine immunotherapy for immune suppressed patients
HK1107267A (en) Immunotherapy for reversing immune suppression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090309

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091203

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111024